-
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2025 Earnings Call Transcript
02 Aug 2025 12:35 GMT
… cross-trial comparisons, patients taking a 4-drug … first and only FDA-approved treatment for this debilitating … of profits from ARCALYST and higher royalty … disconnect.
Follow Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) Follow Regeneron Pharmaceuticals Inc. …
-
Regeneron Reports Second Quarter 2025 Financial and Operating Results
01 Aug 2025 10:30 GMT
… the treatment of obesity. The trial demonstrated … biotechnology company that invents, develops, and commercializes life-transforming medicines … regeneron.com
christina.chan@regeneron.com
TABLE 1
REGENERON PHARMACEUTICALS … sales of ARCALYST®, which are …
-
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q2 2025 Earnings Call Transcript
30 Jul 2025 13:03 GMT
… July 29, 2025
Kiniksa Pharmaceuticals, Ltd. beats earnings expectations … Phase III pivotal trial, supporting FDA approval of ARCALYST in recurrent … good persistence from the Medicare Part D patients who … efforts to shorten the treatment journey for patients by …
-
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution
29 Jul 2025 11:30 GMT
… 47;3 clinical trial in recurrent … Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the U.S. Food and Drug … doctor whether you should receive any vaccines before you begin treatment with ARCALYST.
Medicines … , our clinical trials; delays or …
-
Regeneron Pharmaceuticals Earnings Preview: What to Expect
26 Jul 2025 12:55 GMT
… Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines … , Evkeeza, Inmazeb Arcalyst and Zaltrap. The biotechnology company is expected to … sales of its key drug Eylea, amid increased competition …
-
Comprehensive Clinical Analysis of Rilonacept in the Treatment of Cryopyrin-Associated Periodic Syndromes: A Systematic Review
09 May 2025 10:21 GMT
… drug indication in the treatment of CAPS, making it the first approved medication … -rilonacept-regeneron-withdrawal- … ARCALYST [Rilonacept]. Available from: https://www.accessdata.fda.gov/drugsatfda …
35. Novartis Pharmaceuticals Corporation EH, NJ …
-
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2025 Earnings Call Transcript
01 May 2025 12:21 GMT
… which is the only FDA-approved treatment for recurrent pericarditis to … federal changes to the Medicare Part D program, which … to pharmaceuticals, they would not impact ARCALYST supply received from Regeneron. That … we saw in the trials and what patients are …
-
Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution
29 Apr 2025 11:30 GMT
… ;3 clinical trial in recurrent … Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the U.S. Food and Drug … doctor whether you should receive any vaccines before you begin treatment with ARCALYST.
Medicines … , our clinical trials; delays or …
-
Regeneron Reports First Quarter 2025 Financial and Operating Results
29 Apr 2025 10:30 GMT
… 3 QUASAR trial for the treatment of patients … Biotechnologies (Fujifilm) to manufacture and supply Regeneron's commercial bulk drug … @regeneron.com
christina.chan@regeneron.com
TABLE 1
REGENERON PHARMACEUTICALS … product sales of ARCALYST®, which are …
-
Global Arcalyst (Rilonacept) Market: Key Trends, Market Share, Growth Drivers, And Forecast For 2025-2034
17 Mar 2025 15:59 GMT
… Arcalyst Rilonacept Market?
The increasing demand for personalized medicine … treatments allow for greater precision in addressing disease progression and drug … the Arcalyst Rilonacept Market?
Regeneron Pharmaceuticals Inc. and Kiniksa Pharmaceuticals Ltd. …